canadabiogenix-logo-only-clear-background-landscape
Canada Biogenix Research Reference

PEPTIDE CHEAT SHEET

A fast, honest overview of the leading mechanisms, proposed benefits and current evidence behind every unique peptide or peptide-category research compound in our catalogue.

37 unique entriesAll current peptide-category listings, with duplicate strengths consolidated.
2 printable panelsMetabolic and performance research on page one; repair, immune and neurological research on page two.
Evidence-awareClinical, human, early-stage, preclinical and laboratory evidence are kept distinct.
How external guides work: Select rows include an independently published third-party research or dosing guide. These links are provided for source transparency and further reading; Canada Biogenix does not author, verify or endorse third-party protocols.

Metabolism, Growth Signalling & Mitochondrial Research

Weight regulation, endocrine signalling, energy biology, performance and longevity pathways.

Panel 1 of 2
Peptide / CompoundPrimary Research FocusWhat the Data SuggestsEvidence SnapshotAvailable Format
1MQ
5-Amino-1MQSmall-molecule NNMT inhibitor*Third-party guide ↗
 NNMT, cellular energy handling and adipocyte metabolism.
  • Preclinical work links NNMT inhibition with improved metabolic flexibility.
  • Studied for fat-cell energy expenditure, body-composition and NAD+-salvage pathways.
 Preclinical 5 mg
10 mg
AOD
AOD-9604Modified hGH fragment 176–191Third-party guide ↗
 Fat metabolism without full growth-hormone signalling.
  • Designed to isolate the lipolytic region of human growth hormone.
  • Human studies explored fat oxidation and weight-management outcomes, with mixed efficacy.
 Human, mixed 10 mg
CJC
CJC-1295 No DACShorter-acting GHRH analogueThird-party guide ↗
 Pulsatile growth-hormone and IGF-1 signalling.
  • Studied for increasing endogenous GH pulses rather than supplying GH directly.
  • Commonly researched for recovery, lean-mass, sleep and body-composition pathways.
 Limited human 10 mg
DAC
 Sustained GH and IGF-1 exposure.
  • The Drug Affinity Complex binds albumin and extends activity.
  • Human endocrine studies found prolonged, dose-dependent GH and IGF-1 increases.
 Human research 5 mg
C+I
CJC-1295 + IpamorelinGHRH + ghrelin-receptor blendThird-party guide ↗
 Complementary GH-release pathways.
  • Pairs pituitary GHRH signalling with selective ghrelin-receptor activation.
  • Studied conceptually for stronger GH pulses, recovery, sleep and body composition.
 Blend extrapolation 10 mg
G6
GHRP-6Ghrelin-receptor secretagogueThird-party guide ↗
 Growth-hormone release and appetite signalling.
  • Human endocrine studies show GH release through the GHS-R1a receptor.
  • Known for a pronounced hunger signal; researched for recovery and anabolic pathways.
 Human research 10 mg
IPA
IpamorelinSelective ghrelin-receptor agonistThird-party guide ↗
 Selective GH release with less cortisol/prolactin activity.
  • Produces GH release in human endocrine research.
  • Frequently studied for sleep, recovery, lean tissue and body-composition support.
 Human research 10 mg
TES
TesamorelinStabilized GHRH analogueThird-party guide ↗
 GH/IGF-1 signalling and visceral-fat metabolism.
  • Clinical evidence supports reduction of excess visceral abdominal fat in its approved indication.
  • Also researched for lipid, liver-fat and body-composition effects.
 Clinical moleculeResearch product status is separate. 10 mg
SEM
SemaglutideGLP-1 receptor agonist
 Appetite, glucose control and cardiometabolic outcomes.
  • Extensive clinical trials show improved glycaemic control and substantial average weight reduction.
  • Acts through satiety, insulin signalling and delayed gastric emptying.
 Established clinicalThis is molecule-level evidence. 10 mg
TIR
TirzepatideDual GIP/GLP-1 receptor agonistThird-party guide ↗
 Appetite, glucose regulation and body weight.
  • Clinical trials show strong effects on HbA1c, satiety and average weight reduction.
  • Dual incretin activity often outperforms single-pathway GLP-1 therapy in head-to-head research.
 Established clinicalThis is molecule-level evidence. 10 mg
RETA
RetatrutideGLP-1/GIP/glucagon triple agonistThird-party guide ↗
 Multi-pathway weight, glucose and energy-expenditure research.
  • Late-stage human research reports especially large average weight reductions.
  • Triple agonism may combine appetite control with glucagon-linked energy expenditure.
 Advanced human trialsInvestigational; not an approved therapy. 10 mg
20 mg
MOTS
MOTS-CMitochondrial-derived peptideThird-party guide ↗
 AMPK, metabolic flexibility and cellular stress response.
  • Animal work suggests effects on glucose utilization, exercise capacity and insulin sensitivity.
  • Human studies are exploring age, metabolism and exercise-response associations.
 Early human 10 mg
20 mg
40 mg
NAD
NAD+Cellular coenzyme*
 Redox chemistry, ATP generation, sirtuins and DNA repair.
  • Essential to mitochondrial energy metabolism and hundreds of enzymatic reactions.
  • “Anti-aging” benefits from exogenous NAD+ remain less established than its core biology.
 Established biologySupplemental outcomes remain limited. 500 mg
SLU
SLU-PP-332ERR agonist small molecule*Third-party guide ↗
 Exercise-mimetic metabolism and oxidative muscle biology.
  • Animal studies report increased oxidative fibres, endurance and energy expenditure.
  • Studied as an “exercise mimetic,” but there is no established human efficacy or safety profile.
 Animal research 5 mgRaw powder
SS31
SS-31 / ElamipretideMitochondria-targeted tetrapeptideThird-party guide ↗
 Cardiolipin, electron transport and mitochondrial resilience.
  • Designed to stabilize mitochondrial membranes and reduce oxidative stress.
  • Human trials have explored cardiac, muscular, renal and rare mitochondrial conditions.
 Human clinical research 10 mg
EPI
 Telomerase, circadian signalling and cellular longevity.
  • Cell and animal studies suggest telomerase, antioxidant and gene-regulatory effects.
  • Often associated with sleep and healthy-aging research; robust human confirmation is lacking.
 Mostly preclinical 10 mg
GSH
GlutathioneEndogenous antioxidant tripeptide
 Redox balance, detoxification and oxidative-stress defence.
  • Central to cellular antioxidant recycling and liver conjugation pathways.
  • Human research explores oxidative stress, recovery, skin pigmentation and immune function; delivery route matters.
 Extensive human biology 1500 mg
GHK
GHK-CuCopper-binding tripeptideThird-party guide ↗
 Collagen, extracellular matrix, skin and hair biology.
  • Topical and laboratory research supports collagen, elastin and wound-remodelling pathways.
  • Studied for skin quality, hair-follicle signalling, antioxidant activity and tissue repair.
 Topical human + preclinical 50 mg
100 mg
MT1
Melanotan IMC1R-preferring α-MSH analogue
 Melanin production and photoprotection pathways.
  • Stimulates melanocortin-1 signalling and eumelanin production.
  • A related regulated analogue provides human precedent for photoprotection; research products are distinct.
 Human analogue precedent 10 mg
MT2
Melanotan IIMulti-receptor melanocortin agonistThird-party guide ↗
 Pigmentation, appetite and sexual-response pathways.
  • Human research shows melanogenesis and sexual-response effects through melanocortin receptors.
  • Broader receptor activity also increases variability and adverse-effect concerns.
 Early human 10 mg

Repair, Immune, Neurological & Hormonal Research

Tissue remodelling, inflammation, antimicrobial defence, cognition, sleep and reproductive signalling.

Panel 2 of 2
Peptide / CompoundPrimary Research FocusWhat the Data SuggestsEvidence SnapshotAvailable Format
BPC
BPC-157Gastric pentadecapeptideThird-party guide ↗
 Tendon, ligament, muscle, gut and vascular repair pathways.
  • Animal studies report accelerated healing and effects on nitric oxide, angiogenesis and inflammation.
  • Commonly touted for injury recovery and gut integrity; quality human trials remain sparse.
 Primarily animal 10 mg
TB
TB-500Thymosin β4-related peptideThird-party guide ↗
 Cell migration, actin, angiogenesis and tissue recovery.
  • Thymosin-β4 research suggests wound-repair, vascular and anti-inflammatory activity.
  • Often associated with flexibility and soft-tissue recovery; TB-500-specific human data are limited.
 Mostly preclinical 10 mg
KPV
KPVα-MSH-derived tripeptideThird-party guide ↗
 Inflammatory signalling, gut barrier and skin research.
  • Cell and animal studies report suppression of NF-κB-related inflammatory signalling.
  • Studied for intestinal inflammation, epithelial integrity and antimicrobial interactions.
 Preclinical 10 mg
LL37
LL-37Human cathelicidin peptideThird-party guide ↗
 Antimicrobial defence, biofilms, immunity and wound repair.
  • Strong laboratory evidence shows broad antimicrobial and immune-signalling activity.
  • Studied for biofilms, epithelial repair and inflammatory regulation; clinical translation is early.
 Lab + early human 5 mg
TA1
 T-cell maturation, innate immunity and immune balance.
  • Human studies and use in some countries support immune-modulating activity.
  • Research spans infection response, vaccine response, immune exhaustion and oncology adjunct settings.
 Human clinical research 10 mg
THY
ThymulinZinc-dependent thymic nonapeptideRelated thymic-peptide guide ↗
 Thymic signalling, T-cell biology and neuroendocrine immunity.
  • Preclinical studies suggest immune-balancing and anti-inflammatory actions.
  • Also explored for pain, endocrine signalling and age-associated thymic decline.
 Preclinical / limited human 10 mg
VIP
VIPVasoactive intestinal peptide
 Vasodilation, gut, airway, neuroimmune and inflammatory signalling.
  • Established human biology supports smooth-muscle relaxation, secretion and vasodilation.
  • Research explores airway function, gut motility, neuroprotection and immune regulation.
 Human physiology 10 mg
PNC
PNC-27p53-derived experimental peptide
 Selective cancer-cell membrane disruption.
  • Laboratory studies propose binding to membrane-associated HDM2 and pore formation.
  • Shows intriguing cell-model selectivity, but has no established clinical efficacy or safety.
 Laboratory only 10 mg
SEM
SemaxACTH(4–7)-derived analogueThird-party guide ↗
 Neurotrophic signalling, cognition and cerebral stress response.
  • Preclinical and regional human literature explores BDNF, attention, memory and neuroprotection.
  • Often touted for focus and mental performance; evidence quality and generalizability vary.
 Limited human 10 mg
SEL
SelankTuftsin-derived analogueThird-party guide ↗
 Anxiety, stress resilience, cognition and neuroimmune signalling.
  • Regional human and preclinical work suggests anxiolytic and cognitive effects.
  • Studied for GABAergic modulation, stress response, memory and immune-gene expression.
 Limited human 10 mg
DSIP
DSIPDelta sleep-inducing peptideThird-party guide ↗
 Sleep architecture, stress and neuroendocrine rhythms.
  • Early studies explored sleep onset, sleep quality, pain and stress-hormone signalling.
  • Findings are inconsistent; the “sleep-inducing” name overstates the certainty of current evidence.
 Early human, mixed 15 mg
KISS
 GnRH, LH/FSH and reproductive-axis signalling.
  • Human physiology studies show stimulation of reproductive-hormone signalling.
  • Research explores fertility, ovulation, hypothalamic amenorrhoea and hormone-axis diagnostics.
 Human research 10 mg
OXY
OxytocinEndogenous neuropeptide hormoneThird-party guide ↗
 Reproductive physiology, bonding and social-neural signalling.
  • Established roles in uterine contraction and milk ejection.
  • Research explores social cognition, stress, attachment, pain and appetite, with context-dependent results.
 Established moleculeBroader benefits remain investigational. 10 mg
PT
 Sexual desire and arousal signalling.
  • Clinical molecule acts centrally rather than primarily through blood-flow pathways.
  • Human evidence supports sexual-desire outcomes in a specific approved indication.
 Established clinicalResearch product status is separate. 10 mg
WOL
WolverineBPC-157 + TB-500 blendBPC-157 source guide ↗
 Multi-pathway soft-tissue and recovery research.
  • Combines BPC-157’s proposed gut/vascular repair pathways with TB-500-related cell migration.
  • Popularly touted for tendon, ligament, muscle and mobility support; the blend lacks clinical trials.
 Blend extrapolation 20 mg
GLOW
GLOWBPC-157 + TB-500 + GHK-CuThird-party blend guide ↗
 Tissue recovery, collagen, skin and wound-remodelling pathways.
  • Combines three research pathways involving angiogenesis, cell migration and extracellular matrix.
  • Touted for broader recovery plus skin-quality support; the complete blend is not clinically validated.
 Blend extrapolation 70 mg
KLOW
KLOWKPV + BPC-157 + TB-500 + GHK-Cu
 Inflammation, gut, epithelial, tissue and skin pathways.
  • Adds KPV’s proposed NF-κB and epithelial activity to the GLOW repair framework.
  • Touted as the broadest repair/inflammation blend; combined outcomes remain unproven.
 Blend extrapolation 80 mg
Established clinical
Substantial human evidence exists for the molecule in at least one regulated medical context.
Human research
Human studies exist, but findings, indications or formulations may remain investigational.
Early / mixed
Limited, small, regional or inconsistent human evidence.
Preclinical
Evidence comes mainly from cells, animals or extrapolation from related molecules.
Laboratory only
No reliable evidence of clinical efficacy or safety in humans.
*Not technically peptides: 5-Amino-1MQ and SLU-PP-332 are small molecules, while NAD+ is a coenzyme. They are included because they currently appear in the Canada Biogenix Research Peptides catalogue. Duplicate vial strengths are consolidated into a single reference row.
Research and safety notice: This chart is an educational summary of published research, proposed mechanisms and commonly touted research interests. “What the data suggests” does not mean a benefit is proven, clinically meaningful or expected from a Canada Biogenix product. Many entries have little or no high-quality human trial evidence, and blend effects are extrapolated from their individual components. Evidence relating to an approved pharmaceutical does not confer approval, equivalence, safety or efficacy on a separately sold research material. Canada Biogenix research materials are not intended to diagnose, treat, cure or prevent disease and are not for human or animal use. No dosing, administration or treatment protocol is provided.
Explore Research Peptides Storage & Handling FAQ